All the Drug Class Drugs
Tyrosine Kinase Inhibitor. Imatinib 100 mg, 400 mg. F.C. TABS: 20, 60 x 100 mg; 10, 30 x
Doses of 400 mg or 600 mg should be
admin. once dly., whereas a daily dose
of 800 mg should be admin. as 400 mg
×2/d in the morn. and even.
Tmt. of adult pts. and child. 3 yrs. of age
and above with Ph+ chron. myeloid
leukaemia (Ph+ -CML) in chron. phase
accelerat. phase or blast crisis. Glivec is
also indicat. for the tmt. of adult pts.s
with Kit (CD117) posit. unresect. and/or
metastat. malignant GI strom. tumour.
(GIST). Also indicated for the tmt. of :
Adult pts. with newly diagnosed
Philadelphia chromos. posit. acute
lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy. Adult pts.
with relapsed or refract. Ph + ALL as
monother. Adult pts. with unresect.
(DFSP) and adult pts. with recurrent and/
or metastat. DFSP who are not eligible
for surg. Adult pts. with myelodyspiastic/
myeloproliferative dis.(MDS/MPD) assoc.
with PDGFR ( platelet - derived growth
factor recept. ) gene re- arrangements.
Adult pts. with hypereosinophilic syndr.
(HES) and/or chronic eosinophilic
leukaemia (CEL) who have the FIP1L1-
PDGFRalfa fusion kinase (mutational
analysis or FISH demonstration fo CHIC2
allele deletion) and for pts. with HES and/
or CEL who are FIP1L1-PDGFR alfa fusion
kinase negative . Adult pts. with aggress.
systemic mastocytosis (ASM) without the
D816V c-kit mutation .Adjuvant tmt. of
adult pts. follow. complete gross resec. of
Kit (CD117) positive GIST.
Tyrosine Kinase Inhibitor. Axitinib 1 mg, 5 mg. F.C. TAB: 28, 56, 60, 180 × 5, 1 mg.
Recomm. init. oral dose is 5 mg×2/d. approx. 12 hrs. apart with/without food. Should be swallow. whole with a glass of water. If the pt. vomits or misses a dose, an addit. dose should not be taken. The next prescribed dose should be taken at the usual time. See lit.
Tmt. of advanc. RCC after fail. of one prior syst. therapy.
Tyrosine Kinase Inhibitor. Ruxolitinib Phosphate 5 mg, 10 mg, 15 mg, 20 mg. TAB: blist.: 56, bottle.: 60×5, 15, 20mg
MF: The recomm. start. dose: in is 15
mg ×2/d for pts. with a plat. count
between 100,000/mm³ and 200,000/
mm 3 and 20 mg ×2/d for pts. with a
plat. count of >200,000/mm³.
PV: The recomm. start. dose of is 10
Limited inform. to recommend a start.
dose for pts. with plat. count. between
50,000/mm³ & <100,000/mm³.
The max. recomm. start. dose in these
pts. is 5 mg ×2/d and the pts. should be
Dose modific.: Doses may be titrat. based on safety & efficacy. Tmt. should be discont. for plat. counts less than 50,000/mm³ or absolute neutrophil counts less than 500/mm³. In PV, tmt. should also be interrupt. when haemoglobin is below
8 g/dl. After recov. of blood count. above these levels, dosing may be re-started at 5 mg ×2/d and gradual. incr. based on careful. See. lit.
Myelofibrosis (MF).: Tmt. of dis.-related splenomeg.or sympt. in adult pts. with prim. MF (also known as chron. idiopath. MF), post polycythaem. vera myelofibrosis or post essential thrombocythaem. MF.
Polycythaem. vera (PV).: Tmt. of adult pts. with PV who are resist. to or intolerant of hydroxyurea.
C/I: Hypersens. Preg. Lact.
ALK, Tyrosine Kinase Inhibitor. Lorlatinib 25 mg, 100 mg. F.C. TABS.: 90, 120×25mg, 30×100mg. 100 mg×1/d orally, with/without food, at the same time each day, until dis. progress. or unacceptab. toxic.
Swallow tablets whole. If a dose is missed, then the missed dose should be taken, unless the next dose is due within 4 hrs. If vomit. occurs after lorlatinib cont. with the next scheduled dose. 2 doses should not be taken at the same time to make up for a missed dose. See lit.
Tmt. of pts. with anaplast. lymphom. kinase (ALK)-positive metast. NSCLC whose dis. has progressed on;
crizotinib and at least one other ALK inhib. for metast. dis.;
alectinib as the first ALK inhib. for metast. dis.;
ceritinib as the first ALK inhib. for metast. dis.
C/I: Pts. taking strong CYP3A induc., due to the potential for serious hepatotox. Hypers.
Tyrosine Kinase Inhibitor. Erlotinib 100 mg, 150 mg. TABS: 30 x 100 mg, 150 mg. Non-small
cell lung cancer: 150 mg 1 x dly
without food. Pancreat. cancer: 100 mg
dly without food in comb. with
First-line tmt. locally advanced/metastat.
non-small cell lung cancer (NSCLC) with
EGFR activat. mutats. Tmt. locally.
advanced/metastat. NSCLC aft. fail. of at
least one prior chemother. reg. Monother.
for maint. tmt. pts with locally advanc./
metastat. non-small cell lung cancer
whose disease not progress. aft. 4 cycles of
platinum-based first-line chemother. In
comb. with gemcitabine for first-line tmt.
with locally advanced, unresect./
metastat. pancreat. cancer.
C/I: Hypersens. to erlotinib or excips.
Tyrosine Kinase Inhibitor. Nilotinib (HCl monohydrate) 150 mg, 200 mg. CAPS: 28, 40, 112, 120 x 200 mg, 28, 112
x 150 mg.
Newly diagn. Ph+ CML-CP: recomm.
dose 300 mg x 2 dly.
Pts. with Ph+ CML-CP and CML-AP
resist./intoler. to at least 1 prior ther.
incl. imatinib: recomm. dose 400 mg x
2 dly. See lit.
150 mg, 200 mg: Tmt. adult pts. with newly
diagn. Ph+ CML in chron. phase.
200 mg only: Tmt. of Ph+ CML in chron./
acceler. phase in pts. resist. to/experienc.
signif. toxicity dur. tmt. imatinib.